Major Investors Pile Into Viking Therapeutics Stock

The battle for dominance in the lucrative obesity drug market is intensifying. As industry titans Eli Lilly and Novo Nordisk hold strong positions, Viking Therapeutics is emerging as a formidable competitor. A surge in buying from major institutional investors is raising questions: are the professionals betting on an imminent approval for the company's lead candidate, VK2735?

Recent operational milestones are providing the foundation for investor optimism. On November 19, 2025, Viking Therapeutics announced the early completion of patient recruitment for the pivotal Phase 3 trial (VANQUISH-1) of VK2735, enrolling more participants than originally targeted. The significant interest from both physicians and patients in this dual GLP-1/GIP agonist points toward robust potential demand. The company is strategically testing both injectable and oral formulations to broaden its competitive edge.

"Smart Money" Makes Significant Moves

Activity from institutional investors has notably accelerated. Recent filings reveal that Jump Financial acquired over 460,000 shares. Separately, Norges Bank established a new position worth nearly $47 million in the second quarter. Other firms, including Raymond James and Connor Clark & Lunn, have also substantially increased their holdings. With institutional ownership now standing at approximately 76%, these large-scale investors are sending a powerful signal of conviction.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Wall Street Maintains a Bullish Stance Despite Losses

Financially, the biotechnology firm continues to post losses, as is typical for its development stage. The third-quarter loss per share came in at $0.81, which was wider than the analyst consensus estimate of a $0.67 loss. Despite this, sentiment on Wall Street remains positive. The average price target sits around $87 per share. Several research firms, including Canaccord Genuity and Morgan Stanley, have even raised their targets to above $100.

Insider trading activity also paints a picture of stability. While CEO Brian Lian sold shares in late October, he retains a substantial equity position valued at close to $85 million. CFO Greg Zante followed a similar pattern, maintaining a significant personal investment in the company.

The investment community is now looking ahead to the upcoming 37th Annual Piper Sandler Healthcare Conference. Viking's management team is expected to provide fresh insights into clinical data and its strategy within a favorable regulatory landscape. Their presentation will be crucial for providing fundamental support to the stock's recent upward momentum.